Targeting lipoprotein (a): an evolving therapeutic landscape.

about

The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis.Lipoprotein (a), an independent cardiovascular risk marker Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Lipoprotein(a): A Lipoprotein Whose Time Has Come.

P2860

Q30234123-198FFA15-D08F-41D1-B7A7-F596317816A7 Q33801207-134421F7-5AAC-4503-ABB1-E6EA018DB65D Q38786058-D97FC309-E13B-4D25-9F69-60B986F7688A Q39308941-30C3791D-8813-4B0F-BD64-0DBAC38BF2C6

P2860

Targeting lipoprotein (a): an evolving therapeutic landscape.

Item

http://www.wikidata.org/entity/Q38367355

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Targeting lipoprotein (a): an evolving therapeutic landscape.

@en

type

Item

label

Targeting lipoprotein (a): an evolving therapeutic landscape.

@en

prefLabel

Targeting lipoprotein (a): an evolving therapeutic landscape.

@en

P1476

Targeting lipoprotein (a): an evolving therapeutic landscape.

@en

P2093

Danielle Duffy

http://www.w3.org/2001/XMLSchema#string

Erik Kelly

http://www.w3.org/2001/XMLSchema#string

Lillian C Man

http://www.w3.org/2001/XMLSchema#string

P2860

Lipoprotein(a) as a cardiovascular risk factor: current status

Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events

Antisense oligonucleotides for the treatment of dyslipidaemia

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

The mysteries of lipoprotein(a)

Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease

The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity

Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

P2888

s11883-015-0502-0

P304

502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11883-015-0502-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273152010

http://www.w3.org/2001/XMLSchema#string

P6179

1004815103

http://www.w3.org/2001/XMLSchema#string

P698

25736345

http://www.w3.org/2001/XMLSchema#string

P921

LPA

lipoprotein

Targeting lipoprotein (a): an evolving therapeutic landscape.

about

P2860

P2860

Targeting lipoprotein (a): an evolving therapeutic landscape.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P921